Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine: a five-year review

P E Stokes1

  • 1Payne Whitney Clinic, New York Hospital, Cornell University Medical Center, New York.

Clinical Therapeutics
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), offers effective depression treatment with fewer side effects than older antidepressants. Its improved tolerability and dosing convenience enhance patient compliance and treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypercortisolemia decreases dexamethasone half-life in rabbit.

Journal of psychiatric research·2002
Same author

New psychopharmacologic treatment strategies.

Annals of internal medicine·2001
Same author

Lithium isotopes: differential effects on renal function and histology.

Bipolar disorders·2001
Same author

Psychomotor performance and monoamine function in bipolar and unipolar affective disorders.

Biological psychiatry·1999
Same author

Ten years of fluoxetine.

Depression and anxiety·1998
Same author

Direct comparison of two widely used activity recorders.

Sleep·1998
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Depression poses significant health and economic burdens.
  • Existing antidepressant therapies often result in inadequate treatment due to side effects and poor patient compliance.
  • Selective Serotonin Reuptake Inhibitors (SSRIs) represent an advancement in pharmacologic management.

Purpose of the Study:

  • To evaluate fluoxetine hydrochloride as a novel pharmacologic agent for depression.
  • To compare the efficacy and side effect profile of fluoxetine with existing antidepressant therapies.
  • To highlight the advantages of fluoxetine in managing depression.

Main Methods:

  • Review of large-scale clinical trials and post-introduction clinical experience with fluoxetine.

Related Experiment Videos

  • Comparative analysis of side effect profiles between fluoxetine, tricyclic antidepressants (TCAs), and other SSRIs (sertraline, paroxetine).
  • Assessment of treatment discontinuation rates due to side effects.

    • Main Results:

    • Fluoxetine demonstrates comparable efficacy to existing antidepressant agents.
    • Fluoxetine treatment is associated with generally mild and transient side effects, leading to lower discontinuation rates compared to TCAs.
    • Fluoxetine offers advantages in dosing (once daily, no titration) and overdose safety compared to TCAs.

    Conclusions:

    • Fluoxetine represents a significant advance in the pharmacologic management of depression.
    • Its favorable side effect profile and convenient dosing improve patient compliance and treatment outcomes.
    • Further comparative trials are needed to fully elucidate fluoxetine's advantages over other SSRIs.